版本:
中国

Merck & Co Inc (MRK.N)

MRK.N ( 纽约证券交易所 )

63.88USD
20 Oct 2017
涨跌 (%)

$0.13 (+0.20%)
收盘
$63.75
开盘
$63.81
当日最高
$63.99
当日最低
$63.57
成交量
3,929,277
平均成交量
2,761,567
52 周最高
$66.80
52 周最低
$58.29

Chart for

概况

Merck & Co., Inc.是一家全球保健公司。该公司通过直接销售及由合营公司销售处方药、疫苗、生物治疗药品及动物保健产品提供保健解决方案。该公司通过药品部门运营。该部门直接销售或通过合营公司销售人体健康医药及疫苗产品。人体健康医药产品包括用于治疗人体疾病的治疗剂及预防剂(通常为处方药)。该公司主要向药品批发商及... (更多)

概况

Beta: 0.83
市值(百万): $174,223.41
已发行股本(百万): 2,727.35
股息: 0.47
股息收益率 (%): 2.94

财务指标

  Industry Sector
P/E (TTM): -- 31.71 16.52
EPS (TTM): -- -- --
ROI: -- 14.89 11.32
ROE: -- 16.15 15.18

GlaxoSmithKline adult shingles vaccine wins U.S. approval

Oct 20 The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday. 全文
10/21 06:49

UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. 全文
10/21 00:41

Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care

Oct 20 Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday. 全文
10/21 00:10

CORRECTED-Merck cyber attack may cost insurers $275 mln -Verisk's PCS

NEW YORK, Oct 19 Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. 全文
10/20 06:24

BRIEF-U.S. FDA accepts regulatory submission for lynparza

* U.S. FDA accepts regulatory submission for lynparza® (olaparib) in metastatic breast cancer and grants priority review 全文
10/18 20:58

BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA

* Merck’s KEYTRUDA® (pembrolizumab) more than doubled median overall survival compared to chemotherapy after two years of follow up in first-line treatment of patients with metastatic non-small cell lung cancer with high levels of PD-L1 全文
10/18 19:12

Astra and Merck win speedy review for Lynparza in breast cancer

LONDON, Oct 18 U.S. regulators have granted a priority review to AstraZeneca's ovarian cancer drug Lynparza as a treatment for breast cancer, putting it on track for potential approval in the new disease area during the first quarter of 2018. 全文
10/18 14:46

BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck

* Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer 全文
10/16 22:46

Pharma and medtech industries prepare for hard Brexit

LONDON, Oct 16 Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small service businesses are already relocating to stay inside the bloc. 全文
10/16 21:22

UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research

Oct 12 The Trump Administration threw its support behind a public-private partnership with 11 drug companies to advance a new class of drugs that uses the body's immune system to fight cancer. 全文
10/13 04:09

竞争者

  现值 涨跌额
Johnson & Johnson (JNJ.N) $142.40 +0.36
Pfizer Inc. (PFE.N) $36.42 +0.18
AbbVie Inc (ABBV.N) $96.10 -0.38
Eli Lilly and Co (LLY.N) $87.23 +0.87
Bristol-Myers Squibb Co (BMY.N) $64.42 -0.25
Bristol-Myers Squibb Co (BMYMP.PK) $1,088.70 +38.70

收益 vs. 预测